Which drug works best for deadly fungus? researchers dig into past records
NCT ID NCT07191756
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 150 people treated for mucormycosis, a rare but serious fungal infection. Researchers compare two drugs—amphotericin B and isavuconazole—to see which leads to better survival and fewer side effects. The goal is to help doctors choose the best treatment for future patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Sep 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study will analyze a retrospective cohort of patients with a confirmed diagnosis of mucormycosis who were treated at one of three participating hospitals. The study population will be divided into two groups based on the primary antifungal therapy they received: (1) those who received amphotericin B-based therapy (any formulation), and (2) those who received isavuconazole. Data from eligible patients' medical records will be extracted to form the final study dataset. Additionally, relevant patient data from studies identified via a systematic PubMed literature review may be included to supplement the analysis.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Confirmed diagnosis of mucormycosis based on histopathology, culture, or typical radiographic findings in accordance with established guidelines. 2. Received primary antifungal treatment for mucormycosis with either amphotericin B (any formulation) or isavuconazole for at least 48 hours. 3. Had at least one follow-up assessment after initiation of antifungal therapy to evaluate treatment response. 4. Medical records from the participating hospitals are sufficiently complete for data extraction regarding treatment and outcomes. Exclusion Criteria: * Patients who were not treated with amphotericin B or isavuconazole; and patients who did not have mucormycosis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mucormycosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangxi Medical University
Nanning, Guangxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a prosthetic device restore quality of life after facial defects?
- Can a gentler antifungal drug protect liver transplant patients from deadly mold without risking organ rejection?
- Custom 3D-Printed titanium implants could rebuild faces after injury or surgery
- Cresemba under the microscope: Real-World safety check for fungal infections
- Tailoring antifungal doses for seniors: a precision approach
- COVID-19's hidden toll: fungal infections rise in transplant patients